These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 22269465)

  • 1. Cardiomyocytes derived from human pluripotent stem cells for drug screening.
    Zeevi-Levin N; Itskovitz-Eldor J; Binah O
    Pharmacol Ther; 2012 May; 134(2):180-8. PubMed ID: 22269465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiomyocytes derived from human embryonic stem cells - characteristics and utility for drug discovery.
    Steel D; Hyllner J; Sartipy P
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):133-40. PubMed ID: 19152222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stem cells for drug screening.
    Laposa RR
    J Cardiovasc Pharmacol; 2011 Sep; 58(3):240-5. PubMed ID: 21499120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human stem cell-derived cardiomyocytes for pharmacological and toxicological modeling.
    Harding SE
    Ann N Y Acad Sci; 2011 Dec; 1245():48-9. PubMed ID: 22211978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of cardioactive drugs on cardiomyocytes derived from human induced pluripotent stem cells.
    Yokoo N; Baba S; Kaichi S; Niwa A; Mima T; Doi H; Yamanaka S; Nakahata T; Heike T
    Biochem Biophys Res Commun; 2009 Sep; 387(3):482-8. PubMed ID: 19615974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of human-induced pluripotent stem cell-derived cardiomyocytes: bioenergetics and utilization in safety screening.
    Rana P; Anson B; Engle S; Will Y
    Toxicol Sci; 2012 Nov; 130(1):117-31. PubMed ID: 22843568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The application of human embryonic stem cell technologies to drug discovery.
    Sartipy P; Björquist P; Strehl R; Hyllner J
    Drug Discov Today; 2007 Sep; 12(17-18):688-99. PubMed ID: 17826681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity testing using pluripotent stem cell-derived human cardiomyocytes and state-of-the-art bioanalytics: a review.
    Mandenius CF; Steel D; Noor F; Meyer T; Heinzle E; Asp J; Arain S; Kraushaar U; Bremer S; Class R; Sartipy P
    J Appl Toxicol; 2011 Apr; 31(3):191-205. PubMed ID: 21328588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impacts of recent advances in cardiovascular regenerative medicine on clinical therapies and drug discovery.
    Murata M; Tohyama S; Fukuda K
    Pharmacol Ther; 2010 May; 126(2):109-18. PubMed ID: 20156482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological response of human cardiomyocytes derived from virus-free induced pluripotent stem cells.
    Mehta A; Chung YY; Ng A; Iskandar F; Atan S; Wei H; Dusting G; Sun W; Wong P; Shim W
    Cardiovasc Res; 2011 Sep; 91(4):577-86. PubMed ID: 21565833
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concise review: Human pluripotent stem cell-based models for cardiac and hepatic toxicity assessment.
    Sartipy P; Björquist P
    Stem Cells; 2011 May; 29(5):744-8. PubMed ID: 21433222
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the risk of drug-induced proarrhythmia using human induced pluripotent stem cell-derived cardiomyocytes.
    Guo L; Abrams RM; Babiarz JE; Cohen JD; Kameoka S; Sanders MJ; Chiao E; Kolaja KL
    Toxicol Sci; 2011 Sep; 123(1):281-9. PubMed ID: 21693436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospects for pluripotent stem cell-derived cardiomyocytes in cardiac cell therapy and as disease models.
    Freund C; Mummery CL
    J Cell Biochem; 2009 Jul; 107(4):592-9. PubMed ID: 19449339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays.
    Harris K; Aylott M; Cui Y; Louttit JB; McMahon NC; Sridhar A
    Toxicol Sci; 2013 Aug; 134(2):412-26. PubMed ID: 23690542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation and enrichment of cardiomyocytes from human pluripotent stem cells.
    Xu C
    J Mol Cell Cardiol; 2012 Jun; 52(6):1203-12. PubMed ID: 22484618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiomyocyte differentiation of pluripotent stem cells and their use as cardiac disease models.
    Dambrot C; Passier R; Atsma D; Mummery CL
    Biochem J; 2011 Feb; 434(1):25-35. PubMed ID: 21269276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiomyocytes derived from pluripotent stem cells: progress and prospects from China.
    Yang HT; Zhang M; Huang J; Liang H; Zhang P; Boheler KR
    Exp Cell Res; 2013 Jan; 319(2):120-5. PubMed ID: 23022397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiomyocytes from human pluripotent stem cells in regenerative medicine and drug discovery.
    Braam SR; Passier R; Mummery CL
    Trends Pharmacol Sci; 2009 Oct; 30(10):536-45. PubMed ID: 19762090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Directed differentiation of pluripotent stem cells: from developmental biology to therapeutic applications.
    Irion S; Nostro MC; Kattman SJ; Keller GM
    Cold Spring Harb Symp Quant Biol; 2008; 73():101-10. PubMed ID: 19329573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A small molecule that promotes cardiac differentiation of human pluripotent stem cells under defined, cytokine- and xeno-free conditions.
    Minami I; Yamada K; Otsuji TG; Yamamoto T; Shen Y; Otsuka S; Kadota S; Morone N; Barve M; Asai Y; Tenkova-Heuser T; Heuser JE; Uesugi M; Aiba K; Nakatsuji N
    Cell Rep; 2012 Nov; 2(5):1448-60. PubMed ID: 23103164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.